# Iambic Therapeutics

Source: https://onco.cc/companies/iambic-therapeutics/  
OnCo record `iambic-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.

## Summary

Iambic Therapeutics, based in San Diego, has AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2 and CDK4 inhibitor. IAM1363, a brain-penetrant HER2 inhibitor, and IAM-H1 entered phase 1 between 2024 and 2025, and its NeuralPLexer models predict structure and binding. OnCo links it to HER2 as a target and to AI-driven drug and target discovery. Whether a brain-penetrant HER2 inhibitor can treat brain metastases better than existing HER2 drugs is the clinical question that matters most. The HER2 target page carries the competitive field.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: ai
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.iambic.ai

## Sources

- Official website: https://www.iambic.ai

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- targets: [HER2](https://onco.cc/targets/her2/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/)

---
JSON: https://onco.cc/api/v1/entities/iambic-therapeutics.json